Article
No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patients.
Pharmacogenomics - 1 Mar 2017
Deflesselle Eric, Verstuyft Céline, Petit Anne-Cécile, Hardy Patrick, David Denis J, Falissard Bruno, Fève Bruno, Rigal Laurent, Becquemont Laurent, Corruble Emmanuelle, Colle Romain
Abstract excerpt
AIM: NTRK2 is the main receptor of the brain derived neurotrophic factor, which is involved in antidepressant efficacy. We assessed the impact of eight NTRK2 SNPs pertaining to response and remission after antidepressant treatment in depressed patients. PATIENTS & METHODS: In a naturalistic study, 569 patients with a major depressive episode requiring a new antidepressant treatment were genotyped for eight NTRK2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
